KyungDong Pharm home
Prescription Medicines

Levopren Tab.

Product Category
Gastrointestinal motility normalizer
Active Ingredients
Levosulpiride
Appearance
white round tablet
Reimbursement Code
648100460
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Levosulpiride (KP) ----- 25mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: magnesium stearate, low-substituted hydroxypropyl cellulose, crospovidone, povidone

2. Effectiveness
Relief of the following symptoms caused by functional dyspepsia: abdominal bloating, epigastric discomfort, heartburn, burping, nausea, and vomiting.

3. Dosage and dosage
Adults: Administer levosulpiride 25 mg orally three times a day before meals.

4. Precautions for use
1. Do not administer to the following patients.
1) Pregnant women, women who may be pregnant, or lactating women
2) Patients for whom gastrointestinal motility stimulation is harmful (e.g., patients with gastrointestinal bleeding, mechanical disorders, or perforation)
3) Patients with pheochromocytoma (tumor may cause hypertension due to catecholamine release).
4) Patients with hypersensitivity or intolerance to this drug
5) Patients with epilepsy, manic state, and manic stage of manic depression
6) Patients with malignant mastopathy (it is believed that there is a correlation between the prolactin hypersecretion effect of most psychotropic drugs and breast dysplasia).
7) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients.
1) Patients with high blood pressure
2) Children (Be careful not to overdose as extrapyramidal symptoms are likely to occur.)
3) Elderly people

3. Adverse reactions
1) Endocrine system: Occasionally, amenorrhea, excessive galactorrhea, and gynecomastia, which are presumed to be caused by abnormalities in the endocrine function regulation of the diencephalon (abnormal gonadotropin secretion and prolactin secretion), may occur, so observe thoroughly and immediately stop taking the medication if any abnormalities appear.
2) Extrapyramidal system: In rare cases, tremors, tongue twisting, and nervousness may occur, so in such cases, discontinue medication.
3) Tardive dyskinesia: In rare cases, involuntary movements around the mouth may occur due to long-term administration and may persist even after discontinuation of drug administration.
4) Digestive system: Sometimes dry mouth, heartburn, nausea, vomiting, diarrhea, constipation, etc. may occur.
5) Circulatory system: high blood pressure, arrhythmia
6) Neuroleptic Malignant Syndrome: Neuroleptic malignant syndrome has been reported while this drug was administered as a neuroleptic during antipsychotic treatment. Symptoms related to this include high fever, muscle stiffness, inability to move, autonomic nervous system disorders (irregular pulse and blood pressure, sweating, tachycardia, arrhythmia), and changes in the state of consciousness that can lead to numbness or coma. If these symptoms appear, immediately discontinue the administration of antipsychotic drugs, including this drug, if possible, and provide intensive symptomatic treatment such as body cooling and hydration. When these symptoms appear, an increase in white blood cells and serum creatine kinase (CK) frequently occur, and decreased renal function accompanied by myoglobinuria may occur. There are also reports that a patient with neuroleptic malignant syndrome died after developing persistent high fever, impaired consciousness, difficulty breathing, circulatory collapse and dehydration, and acute renal failure.
7) Others: In rare cases, rash and swelling may occur, so in such cases, discontinue drug administration. Additionally, hot flashes, fatigue, insomnia, drowsiness, dizziness, and grogginess may sometimes occur, and in rare cases, erectile dysfunction may occur.
8) In case of long-term administration, adverse reactions such as amenorrhea, gynecomastia, excessive milk secretion, and increase or decrease in sexual desire may occur. Similar to other neuroleptics, this is an effect on the function of the hypothalamus, pituitary, gonad, and second cervical vertebra, and is reversible.

4. General precautions
1) Due to endocrine dysfunction in the diencephalon, secretion of prolactin increases and there is an adverse reaction of milk leakage, so be sure to inform the patient before prescribing.
2) Since it may cause adverse reactions such as endocrine dysfunction of the diencephalon and extrapyramidal symptoms, it should be administered with due consideration of effectiveness and safety.
3) It is advisable for patients taking this drug to avoid driving a car or operating machinery that requires concentration.
4) High-dose levosulpiride preparations are prescribed as atypical neuroleptics in some overseas countries. QT prolongation, ventricular arrhythmia (e.g., Torsades de Pointes), ventricular tachycardia, ventricular fibrillation, and cardiac arrest have been rarely observed with atypical antipsychotics in the same class. Caution is required as these cardiac abnormalities can very rarely lead to death. Additionally, as a result of a clinical trial targeting elderly dementia patients taking atypical antipsychotics, it was observed that taking antipsychotics increased cerebrovascular events by about three times compared to placebo. The mechanism of these adverse reactions is not yet known, and an increased risk in other antipsychotic drugs and other patient groups cannot be ruled out. Therefore, when administering this drug to patients with stroke risk factors, it must be administered carefully according to the approved dosage and dosage.

5. Interaction
1) The effect of this drug on gastrointestinal motility may be antagonistic to anticholinergic drugs (atropine, methylscopolamine, etc.), narcotics, and painkillers, so do not administer in combination.
2) Since the symptoms of nausea, vomiting, and loss of appetite, which are indicators of saturation of digitalis preparations, may become invisible, patients receiving digitalis preparations should be carefully observed and administered carefully.
3) Because endocrine dysfunction or extrapyramidal symptoms are likely to occur due to combined use with other benzamide drugs (methoclopramide, tiapride, etc.), sufficient observation and careful administration are required when using these drugs together.
4) When co-administered with psychopharmacological drugs, unexpected adverse reactions may occur due to interactions, so special caution should be exercised and do not be administered simultaneously with alcohol.
5) When this drug is administered in combination with drugs that prolong the QT interval, the risk of cardiac arrhythmia increases, so sufficient caution and observation are required when using this drug together.
6) Do not co-administer with drugs that cause electrolyte disorders.

6. Administration to pregnant and lactating women
In animal testing, it has been reported that there is a risk of birth defects in the fetus, and the safety of administration during pregnancy has not been established, so it should not be administered to pregnant women or women who may be pregnant.
Because safety for newborns has not been established, it should not be administered to lactating women.

7. Administration to elderly people
It is mainly excreted through the kidneys, but elderly people often have reduced renal function, so there is a risk that high plasma concentrations may persist, so administer with caution, paying attention to the occurrence of side effects (extrapyramidal symptoms, etc.) and paying attention to the dosage and administration interval.

8. Other
1) The anti-emetic effect can prevent symptoms of poisoning caused by other drugs, intestinal obstruction, or vomiting caused by brain tumors, so observe sufficiently and administer carefully.
2) There are reports that it causes testicular atrophy in animal chronic toxicity experiments and a decrease in pregnancy rate in reproduction experiments.
3) There are reports that as a result of long-term administration of high doses to rats and mice, the incidence of tumors in the pituitary gland and mammary glands is higher than in the control group.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 300 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 3items

No.Product NameDetailsDate of ChangeDownload
3Levopren Tab.Levoprene Tablet (Precautions for use)2013.01.30HWPLevopren Tablet_Change in Permission.hwp
2Levopren Tab.Levoprene Tablet (efficacy, dosage, directions for use...2012.12.31HWPLevopren Tablet_Permission Change Order.hwp
1Levopren Tab.Levoprene Tablet (Precautions for use)2009.10.07HWPLevoprene Tablet (Precautions for Use) Changed (2009.10.07).hwp